Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma

Authors: Bin Wei, Qin Han, Lijuan Xu, Xiaohui Zhang, Jing Zhu, Li Wan, Yan Jin, Zhaoye Qian, Jingjing Wu, Yong Gao, Jianwei Zhou, Xiaofei Chen

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

DNA damage repair genes JWA, XRCC1 and BRCA1 were associated with clinical outcomes and could convert the response to the cisplatin-based therapy in some carcinomas. The synergistic effects of JWA, XRCC1 and BRCA1 mRNA expression on personalized therapy remain unknown in advanced esophageal squamous cell carcinoma (ESCC).

Methods

We employed quantitative real-time polymerase chain reaction (qPCR) to determine the expression of JWA, XRCC1 and BRCA1 mRNA in paraffin-embedded specimen from 172 patients with advanced ESCC who underwent the first-line cisplatin-or docetaxel-based treatments.

Results

High JWA or XRCC1mRNA expression was correlated with longer median overall survival (mOS) in all the patients (both P < 0.001) or in subgroups with different regimens (all P < 0.05), but not correlated with response rate (RR, all P > 0.05). Multivariate analysis revealed that high JWA (HR 0.22; 95% CI 0.13-0.37; P < 0.001) or XRCC1 (HR 0.36; 95% CI 0.21-0.63; P < 0.001) mRNA expression emerged as the independent prognostic factors for ESCC patients in this cohort. But no significant difference in prognostic efficacy was found between JWA plus XRCC1 and JWA alone through ROC analysis. Further subgroup analysis showed cisplatin-based treatments could improve mOS of patients with low JWA expression (P < 0.05), especially in those with low BRCA1 expression simultaneously (P < 0.001); while in patients with high JWA expression, high BRCA1 mRNA expression was correlated with increased mOS in docetaxel-based treatments (P = 0.044).

Conclusion

JWA, XRCC1and BRCA1 mRNA expression could be used as predictive markers in molecular staging for personalized therapy in patients with advanced ESCC who received first-line cisplatin- or docetaxel-based treatments.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
2.
Pennathur A, Farkas A, Krasinskas AM, Ferson PF, Gooding WE, Gibson MK, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009;87(4):1048–54. discussion 1054-1055.CrossRefPubMedPubMedCentral
3.
Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.CrossRefPubMed
4.
Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25(2):180–6.CrossRefPubMed
5.
Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon 2nd JE, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005;11(6):2215–21.CrossRefPubMed
6.
Alexander BM, Wang XZ, Niemierko A, Weaver DT, Mak RH, Roof KS, et al. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):164–71.CrossRefPubMed
7.
Gao Y, Zhu J, Zhang X, Wu Q, Jiang S, Liu Y, et al. BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. PLoS One. 2013;8(1):e52589.CrossRefPubMedPubMedCentral
8.
Huang S, Shen Q, Mao WG, Li AP, Ye J, Liu QZ, et al. JWA, a novel signaling molecule, involved in the induction of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun. 2006;341(2):440–50.CrossRefPubMed
9.
Chen R, Qiu W, Liu Z, Cao X, Zhu T, Li A, et al. Identification of JWA as a novel functional gene responsive to environmental oxidative stress induced by benzo[a]pyrene and hydrogen peroxide. Free Radic Biol Med. 2007;42(11):1704–14.CrossRefPubMed
10.
Shen L, Xu W, Li A, Ye J, Zhou J. JWA enhances As(2)O(3)-induced tubulin polymerization and apoptosis via p38 in HeLa and MCF-7 cells. Apoptosis. 2011;16(11):1177–93.CrossRefPubMed
11.
Chen H, Bai J, Ye J, Liu Z, Chen R, Mao W, et al. JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. Cell Signal. 2007;19(6):1315–27.CrossRefPubMed
12.
Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, et al. JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene. 2010;29(8):1227–37.CrossRefPubMed
13.
Wang S, Gong Z, Chen R, Liu Y, Li A, Li G, et al. JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks. Nucleic Acids Res. 2009;37(6):1936–50.CrossRefPubMedPubMedCentral
14.
Caldecott KW, McKeown CK, Tucker JD, Ljungquist S, Thompson LH. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol. 1994;14(1):68–76.CrossRefPubMedPubMedCentral
15.
Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J. 1996;15(23):6662–70.PubMedPubMedCentral
16.
Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de MJ, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 1998;18(6):3563–71.CrossRefPubMedPubMedCentral
17.
Vidal AE, Boiteux S, Hickson ID, Radicella JP. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J. 2001;20(22):6530–9.CrossRefPubMedPubMedCentral
18.
Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko DD, et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 2001;104(1):107–17.CrossRefPubMed
19.
Fan J, Otterlei M, Wong HK, Tomkinson AE, Wilson 3rd DM. XRCC1 co-localizes and physically interacts with PCNA. Nucleic Acids Res. 2004;32(7):2193–201.CrossRefPubMedPubMedCentral
20.
Dai L, Wang K, Zhang J, Lv Q, Wu X, Wang Y. XRCC1 gene polymorphisms and esophageal squamous cell carcinoma risk in Chinese population: A meta-analysis of case-control studies. Int J Cancer. 2009;125(5):1102–9.CrossRefPubMed
21.
Qiao W, Wang T, Zhang L, Tang Q, Wang D, Sun H. Association study of single nucleotide polymorphisms in XRCC1 gene with the risk of gastric cancer in chinese population. Int J Biol Sci. 2013;9(7):753–8.CrossRefPubMedPubMedCentral
22.
Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, et al. Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. Int J Cancer. 2013;133(8):2004–9.CrossRefPubMedPubMedCentral
23.
Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y, et al. Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res. 2012;18(10):2987–96.CrossRefPubMed
24.
Wu X, Chen H, Gao Q, Bai J, Wang X, Zhou J, et al. Downregulation of JWA promotes tumor invasion and predicts poor prognosis in human hepatocellular carcinoma. Mol Carcinog. 2014;53(4):325–36.CrossRefPubMed
25.
Chen Y, Xia X, Wang S, Wu X, Zhang J, Zhou Y, et al. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients. J Gastroenterol. 2013;48(9):1034–44.CrossRefPubMed
26.
27.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMed
28.
Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene. 2003;22(23):3548–53.CrossRefPubMed
29.
Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.CrossRefPubMed
30.
Castellsague X, Munoz N, De Stefani E, Victora CG, Castelletto R, Rolon PA, et al. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer. 1999;82(5):657–64.CrossRefPubMed
31.
Morita M, Saeki H, Mori M, Kuwano H, Sugimachi K. Risk factors for esophageal cancer and the multiple occurrence of carcinoma in the upper aerodigestive tract. Surgery. 2002;131(1 Suppl):S1–6.CrossRefPubMed
32.
Hidaka H, Hotokezaka M, Nakashima S, Uchiyama S, Maehara N, Chijiiwa K. Sex difference in survival of patients treated by surgical resection for esophageal cancer. World J Surg. 2007;31(10):1982–7.CrossRefPubMed
33.
Bode AM, Dong Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol. 2000;1:181–8.CrossRefPubMed
34.
Hoeijmakers J. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–74.CrossRefPubMed
35.
Toh Y, Oki E, Ohgaki K, Sakamoto Y, Ito S, Egashira A, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol. 2010;15(2):135–44.CrossRefPubMed
36.
Williams C, Lin CY. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. E Cancer Med Sci. 2013;7:370.
37.
Huang S, Shen Q, Mao WG, Li AP, Ye J, Liu QZ, et al. JWA, a novel signaling molecule, involved in all-trans retinoic acid induced differentiation of HL-60 cells. J Biomed Sci. 2006;13(3):357–71.CrossRefPubMed
38.
Weber-Nordt RM, Mertelsmann R, Finke J. The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma. 1998;28(5-6):459–67.CrossRefPubMed
39.
Sjolund J, Manetopoulos C, Stockhausen MT, Axelson H. The Notch pathway in cancer: differentiation gone awry. Eur J Cancer. 2005;41(17):2620–9.CrossRefPubMed
40.
Teo JL, Kahn M. The Wnt signaling pathway in cellular proliferation and differentiation: a tale of two coactivators. Adv Drug Deliv Rev. 2010;62(12):1149–55.CrossRefPubMed
41.
Sak SC, Harnden P, Johnston CF, Paul AB, Kiltie AE. APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res. 2005;11(17):6205–11.CrossRefPubMed
42.
Liu X, Wang S, Xia X, Chen Y, Zhou Y, Wu X, et al. Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer. PLoS One. 2012;7(12):e52348.CrossRefPubMedPubMedCentral
43.
Ban S, Michikawa Y, Ishikawa K, Sagara M, Watanabe K, Shimada Y, et al. Radiation sensitivities of 31 human oesophageal squamous cell carcinoma cell lines. Int J Exp Pathol. 2005;86(4):231–40.CrossRefPubMedPubMedCentral
44.
Shin JS, Tut TG, Ho V, Lee CS. Predictive markers of radiotherapy-induced rectal cancer regression. J Clin Pathol. 2014;67(10):859–64.CrossRefPubMed
45.
Zhao HJ, Hosoi Y, Miyachi H, Ishii K, Yoshida M, Nemoto K, et al. DNA-dependent protein kinase activity correlates with Ku70 expression and radiation sensitivity in esophageal cancer cell lines. Clin Cancer Res. 2000;6(3):1073–8.PubMed
Metadata
Title
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma
Authors
Bin Wei
Qin Han
Lijuan Xu
Xiaohui Zhang
Jing Zhu
Li Wan
Yan Jin
Zhaoye Qian
Jingjing Wu
Yong Gao
Jianwei Zhou
Xiaofei Chen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1364-0

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas

Research article

Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim

Research article

Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression

Research article

Effects of payer status on breast cancer survival: a retrospective study

Research article

Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase

Research article

Household inhalants exposure and nasopharyngeal carcinoma risk: a large-scale case-control study in Guangdong, China
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits